Want to join the conversation?
$CVS said in 4Q15, specialty revenues increased 32% and outpaced market growth rates. The Medicare Part D business had a successful 2016 annual enrollment period. $CVS is combining operational infrastructures and developing programs to improve work streams and expects to complete the majority of Omnicare integration activities by year-end.
$BABA seems to be on a roll! But increasing its yearly sales outlook from 48% to 54% seems over-expectation from the company's part, doesn't it?
$JNJ down 2% in pre-market trading. Earnings beat expectations, but sales disappointed. Johnson is cautious on its outlook. How it will perform in the future?